文献速递精神分裂症与精神病性障碍

精神分裂症抗精神病药单药治疗联合42种药物策略的疗效:系统综述与荟萃分析证据质量评价

Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

荟萃分析质量高而原始研究质量低,效应量与研究质量呈负相关,目前无法推荐任一联合策略。

要点

  • 荟萃分析方法学质量高(平均9/11),但纳入原始研究质量低(平均2.8/8)。
  • 效应量与作者推荐正相关,却与研究质量负相关,推荐可信度受限。

核心结论

  • 效应量与荟萃分析作者推荐正相关,却与原始研究质量负相关,降低推荐可信度。
  • 基于当前荟萃分析证据,无法为精神分裂症患者推荐任一联合策略。

研究设计与样本

  • 系统检索PubMed与PsycInfo至2016年5月13日,纳入比较抗精神病药联合其他药物与安慰剂或单药治疗的随机临床试验荟萃分析。
  • 采用AMSTAR并增加6项新条目评价荟萃分析方法学质量,效应量以标准化均数差/Hedges g或风险比表示。

主要发现

  • 氯氮平联合策略均未优于对照。
  • 荟萃分析方法学质量平均9分(最高11分),纳入原始研究质量平均2.8分(最高8分)。

关键数值与推荐

  • 主要结局为总症状减轻,次要结局包括阳性症状、阴性症状、作者治疗推荐、研究定义的无效率、认知与抑郁症状、因任何原因停药及无效率或不耐受。
  • 21种干预的荟萃分析完全或部分推荐其使用,推荐与汇总干预的效应量正相关。

临床怎么用

  • 临床不应基于当前荟萃分析证据常规推荐任一抗精神病药联合策略。
  • 对单药治疗反应有限者,联合策略的推荐需权衡低质量原始研究带来的不确定性。
  • 需等待更高质量试验和基于患者的荟萃分析来确定可能获益的亚人群。

局限性

  • 纳入荟萃分析的原始研究质量普遍较低(平均2.8/8),限制结论可靠性。
  • 效应量与原始研究质量呈负相关,提示高质量研究下效应可能更小。
  • 无法确定哪些亚人群可能从联合治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Limited treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing. OBJECTIVE: To summarize and compare the meta-analytically determined efficacy of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia. DATA SOURCES: Systematic search of PubMed and PsycInfo until May 13, 2016. STUDY SELECTION: Meta-analyses of randomized clinical trials comparing the efficacy of antipsychotic drugs combined with other antipsychotic or nonantipsychotic medications vs placebos or antipsychotic monotherapy among adults with schizophrenia. DATA EXTRACTION AND SYNTHESIS: Independent reviewers extracted the data and assessed the quality of the methods of the included meta-analyses using A Measurement Tool to Assess Systematic Reviews (AMSTAR), adding 6 new items to rate their quality. Effect sizes, expressed as standardized mean difference /Hedges g or risk ratio, were compared separately for combinations with any antipsychotic drug and for combinations with clozapine. MAIN OUTCOMES AND MEASURES: The primary outcome was total symptom reduction. Secondary outcomes included positive and negative symptoms, treatment recommendations by authors, study-defined inefficacies, cognitive and depressive symptoms, discontinuation of treatment because of any cause, and inefficacies or intolerabilities. RESULTS: Of 3397 publications, 29 meta-analyses testing 42 combination strategies in 381 individual trials and among 19 833 participants were included. For total symptom reductions, 32 strategies that augmented any antipsychotic drug and 5 strategies that augmented clozapine were examined. Fourteen combination treatments outperformed controls (standard mean difference/Hedges g, -1.27 [95% CI, -2.35 to -0.19] to -0.23 [95% CI, -0.44 to -0.02]; P = .05). No combination strategies with clozapine outperformed controls. The quality of the methods of the meta-analyses was generally high (mean score, 9 of a maximum score of 11) but the quality of the meta-analyzed studies was low (mean score, 2.8 of a maximum score of 8). Treatment recommendations correlated with the effect size (correlation coefficient, 0.22; 95% CI, 0.35-0.10; P < .001), yet effect sizes were inversely correlated with study quality (correlation coefficient, -0.06; 95% CI, 0.01 to -0.12; P = .02). CONCLUSIONS AND RELEVANCE: Meta-analyses of 21 interventions fully or partially recommended their use, with recommendations being positively correlated with the effect sizes of the pooled intervention. However, the effect sizes were inversely correlated with meta-analyzed study quality, reducing confidence in these recommendations. Higher-quality trials and patient-based meta-analyses are needed to determine whether subpopulations might benefit from combination treatment, as no single strategy can be recommended for patients with schizophrenia based on the current meta-analytic literature.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry. 2017. PMID: 28514486. doi:10.1001/jamapsychiatry.2017.0624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。